Sodium-glucose cotransporter 2 inhibitors’ mechanisms of action in heart failure

doi:10.4239/wjd.v11.i7.269

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9844)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

812

WORD

139

HTML

5521

Figures (1-1)

269

Tables (1-2)

214

Sum=6955

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

492

Download

594

Sum=1086

Publishing Process of This Article

Item

Count

Browse

679

Download

1124

Sum=1803

Jul 15, 2020 (publication date) through Apr 24, 2024

Times Cited of This Article

Times Cited (19)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Diabetes. Jul 15, 2020; 11(7): 269-279
Published online Jul 15, 2020. doi: 10.4239/wjd.v11.i7.269

Table 2 Ongoing larger clinical trials of sodium-glucose cotransporter 2 inhibitors in heart failure

Trial	Drug	Ejection fraction	Diabetic/nondiabetic
Emperor-reduced	empagliflozin	HFrEF	Both
Emperor-preserved	empagliflozin	HFpEF	Both
Deliver	dapagliflozin	HFpEF	Both

HFrEF: Heart failure with reduced ejection fraction; HFpEF: Heart failure with preserved ejection fraction.

Citation: Grubić Rotkvić P, Cigrovski Berković M, Bulj N, Rotkvić L, Ćelap I. Sodium-glucose cotransporter 2 inhibitors’ mechanisms of action in heart failure. World J Diabetes 2020; 11(7): 269-279
URL: https://www.wjgnet.com/1948-9358/full/v11/i7/269.htm
DOI: https://dx.doi.org/10.4239/wjd.v11.i7.269